Antioxidants (Oct 2022)

Antioxidant Response in Human X-Linked Adrenoleukodystrophy Fibroblasts

  • Sara Petrillo,
  • Jessica D’Amico,
  • Francesco Nicita,
  • Caterina Torda,
  • Gessica Vasco,
  • Enrico S. Bertini,
  • Marco Cappa,
  • Fiorella Piemonte

DOI
https://doi.org/10.3390/antiox11112125
Journal volume & issue
Vol. 11, no. 11
p. 2125

Abstract

Read online

Redox imbalance, mitochondrial dysfunction, and inflammation play a major role in the pathophysiology of X-linked adrenoleukodystrophy (X-ALD), an inherited neurodegenerative disease caused by mutations in the ABCD1 gene, encoding the protein responsible for peroxisomal import and degradation of very long chain fatty acids (VLCFAs). Therefore, VLCFAs accumulate in tissues and plasma, constituting a pathognomonic biomarker for diagnosis. However, the precise role of VLCFA accumulation on the diverse clinical phenotypes of X-ALD and the pathogenic link between VLCFAs and oxidative stress remain currently unclear. This study proposes ferroptosis as a crucial contributor to the disease development and progression. The expression profiles of “GPX4-glutathione” and “NQO1-CoQ10” ferroptosis pathways have been analyzed in fibroblasts of one patient with AMN, the late onset and slowly progressive form of X-ALD, and in two patients with cALD, the cerebral inflammatory demyelinating form of early childhood. Furthermore, as no effective treatments are currently available, especially for the rapidly progressing form of X-ALD (cALD), the efficacy of NAC treatment has also been evaluated to open the way toward novel combined therapies. Our findings demonstrate that lipid peroxides accumulate in X-ALD fibroblasts and ferroptosis-counteracting enzymes are dysregulated, highlighting a different antioxidant response in patients with AMN and cALD.

Keywords